Raloxifene in breast cancer prevention

Luigi Gennari, Daniela Merlotti, Vincenzo De Paola, Ranuccio Nuti

Research output: Contribution to journalArticlepeer-review


Background: Raloxifene is a benzothiophene, selective estrogen receptor modulator with estrogen-agonist effects in the skeleton and the cardiovascular system but estrogen-antagonist effects in the uterus and the mammary gland. This compound was first approved in different countries for the prevention and treatment of osteoporosis. Objective/methods: We performed a literature search to review available preclinical and clinical data that has led to the recent FDA approval of raloxifene as a chemopreventive agent for breast cancer in postmenopausal women. Results/conclusions: Different placebo-controlled trials indicated that raloxifene is effective in reducing invasive breast cancer risk in postmenopausal women. In a recent comparative study, a similar efficacy between raloxifene and tamoxifen for breast cancer prevention was demonstrated, but raloxifene showed a more favorable safety profile.

Original languageEnglish
Pages (from-to)259-270
Number of pages12
JournalExpert Opinion on Drug Safety
Issue number3
Publication statusPublished - May 2008


  • Breast cancer
  • Chemoprevention
  • Estrogen receptor
  • Raloxifene

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Raloxifene in breast cancer prevention'. Together they form a unique fingerprint.

Cite this